IL316872A - Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists - Google Patents
Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonistsInfo
- Publication number
- IL316872A IL316872A IL316872A IL31687224A IL316872A IL 316872 A IL316872 A IL 316872A IL 316872 A IL316872 A IL 316872A IL 31687224 A IL31687224 A IL 31687224A IL 316872 A IL316872 A IL 316872A
- Authority
- IL
- Israel
- Prior art keywords
- interleukin
- antagonists
- methods
- selectively treating
- treating tendinopathy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Neurology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263343510P | 2022-05-18 | 2022-05-18 | |
| PCT/IB2023/055138 WO2023223263A1 (en) | 2022-05-18 | 2023-05-18 | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL316872A true IL316872A (en) | 2025-01-01 |
Family
ID=87060105
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL316872A IL316872A (en) | 2022-05-18 | 2023-05-18 | Methods of selectively treating tendinopathy using interleukin-17 (il-17) antagonists |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4525914A1 (en) |
| JP (1) | JP2025516723A (en) |
| KR (1) | KR20250011948A (en) |
| CN (1) | CN119546340A (en) |
| AU (1) | AU2023270497A1 (en) |
| CA (1) | CA3257386A1 (en) |
| IL (1) | IL316872A (en) |
| WO (1) | WO2023223263A1 (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL447022A1 (en) * | 2023-12-07 | 2025-06-09 | Wasilczyk Cezary | Pharmaceutical composition for use in the treatment and regeneration of the locomotor system, pharmaceutical composition and method of treatment using the composition |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0417487D0 (en) | 2004-08-05 | 2004-09-08 | Novartis Ag | Organic compound |
| GB0425569D0 (en) | 2004-11-19 | 2004-12-22 | Celltech R&D Ltd | Biological products |
| PL1963368T6 (en) | 2005-12-13 | 2021-02-08 | Eli Lilly And Company | Anti-il-17 antibodies |
| US7910703B2 (en) | 2006-03-10 | 2011-03-22 | Zymogenetics, Inc. | Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use |
| GB0612928D0 (en) | 2006-06-29 | 2006-08-09 | Ucb Sa | Biological products |
| US7767206B2 (en) | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| BRPI0908312A2 (en) | 2008-05-05 | 2015-08-18 | Novimmune Sa | '' Isolated fully human monoclonal antibody, pharmaceutical composition, symptom-relieving method of a clinical indication, and method of relieving a symptom of an autoimmune disease, inflammatory disorder or cell proliferation disorder '' |
| US8790642B2 (en) | 2008-08-29 | 2014-07-29 | Genentech, Inc. | Cross-reactive and bispecific anti-IL-17A/F antibodies |
| CA2737636A1 (en) | 2008-09-29 | 2010-04-01 | Roche Glycart Ag | Antibodies against human il17 and uses thereof |
| AR091116A1 (en) | 2012-05-22 | 2015-01-14 | Bristol Myers Squibb Co | BISPECIFIC ANTIBODIES AND THEIR METHODS OF USE |
| LT2953969T (en) | 2013-02-08 | 2019-12-10 | Novartis Ag | Anti-il-17a antibodies and their use in treating autoimmune and inflammatory disorders |
| EP3027649B1 (en) | 2013-08-01 | 2020-04-01 | F.Hoffmann-La Roche Ag | Tnfa-il-17 bispecific antibodies |
| CN107148283A (en) | 2014-10-31 | 2017-09-08 | 豪夫迈·罗氏有限公司 | Anti-IL-17A and IL-17F cross-reactive antibody variants, compositions comprising the same, and methods of making and using the same |
| AU2018361975A1 (en) * | 2017-11-02 | 2020-05-07 | Novartis Ag | Method of treating tendinopathy using interleukin-17 (IL-17) antagonists |
-
2023
- 2023-05-18 AU AU2023270497A patent/AU2023270497A1/en active Pending
- 2023-05-18 IL IL316872A patent/IL316872A/en unknown
- 2023-05-18 WO PCT/IB2023/055138 patent/WO2023223263A1/en not_active Ceased
- 2023-05-18 CN CN202380052857.5A patent/CN119546340A/en active Pending
- 2023-05-18 JP JP2024568004A patent/JP2025516723A/en active Pending
- 2023-05-18 KR KR1020247041634A patent/KR20250011948A/en active Pending
- 2023-05-18 EP EP23735831.2A patent/EP4525914A1/en not_active Withdrawn
- 2023-05-18 CA CA3257386A patent/CA3257386A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CA3257386A1 (en) | 2023-11-23 |
| KR20250011948A (en) | 2025-01-22 |
| JP2025516723A (en) | 2025-05-30 |
| WO2023223263A1 (en) | 2023-11-23 |
| EP4525914A1 (en) | 2025-03-26 |
| CN119546340A (en) | 2025-02-28 |
| AU2023270497A1 (en) | 2024-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT4303583T (en) | Methods of treating disorders using csf1r inhibitors cross-reference to related applications | |
| JO3559B1 (en) | An antibody FOR TREATING OR PREVENTING MIGRAINE HEADACHE AND METHOD OF THEREOF USE | |
| MX2022008255A (en) | Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies. | |
| NZ754676A (en) | Use of anti-sclerostin antibodies in the treatment of osteogenesis imperfecta | |
| MY184189A (en) | Methods of treating nail and scalp psoriasis | |
| IL257723A (en) | Methods for the treatment of non-radiographic sclerosing spondylitis with the help of interleukin-17 (il-17) antagonists | |
| EA202193345A1 (en) | ANTIBODIES TO NATRIURETIC PEPTIDE RECEPTOR-1 AND METHODS FOR THEIR APPLICATION | |
| EA201890567A1 (en) | CANCER TREATMENT METHOD | |
| AU2022233762A1 (en) | Method of treating diseases using gremlin1 antagonists | |
| ZA202206163B (en) | Methods of treating coronavirus | |
| HK1247562A1 (en) | Method of treating a localized fibrotic disorder using a tnf receptor 2 antagonist | |
| MX2021008716A (en) | Method for treating osteoarthritis pain by administering resiniferatoxin. | |
| IL274214A (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists | |
| AU2016348418A8 (en) | Compositions comprising IL6R antibodies for the treatment of uveitis and macular edema and methods of using same | |
| IL299339A (en) | Antibodies and methods for treating claudin-associated diseases | |
| IL318512A (en) | Methods for the treatment of hypertension via transcranial-focused-ultrasound | |
| IT201900020274A1 (en) | TIP FOR SURGERY AND METHOD OF IMPLEMENTATION | |
| EA202092125A1 (en) | ANTIBODIES AGAINST FOLATE 1 RECEPTOR AND THEIR APPLICATION | |
| AR116668A1 (en) | AGONIST ANTIBODIES AGAINST CD200R AND ITS USES | |
| MX2024001954A (en) | Il-13 antibodies for the treatment of atopic dermatitis. | |
| IL325649A (en) | Method of treating depression using seltorexant | |
| WO2017140684A3 (en) | Methods and pharmaceutical compositions for the treatment of post-operative cognitive dysfunction | |
| IL288003A (en) | Methods of treating cancer using chk1 inhibitors | |
| HUE069670T2 (en) | Composition and method for treatment of multiple sclerosis | |
| HK40026039A (en) | Method of treating tendinopathy using interleukin-17 (il-17) antagonists |